mortality/aging
• at E7.5
|
Allele Symbol Allele Name Allele ID |
Nrbp1tm1.2Dja targeted mutation 1.2, David J Adams MGI:5427570 |
||||||||||||||||
Summary |
3 genotypes
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• at E7.5
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• in tamoxifen-treated mice
|
• moribund as early as 3 days post tamoxifen treatment
• 75% of mice die 9 days after tamoxifen treatment
• mice treated with a low dose of tamoxifen exhibit increased death associated with tumorigenesis
|
• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice
|
• loss of architecture in tamoxifen-treated mice with reduction in numbers of differentiated cells, cells showing dysplastic nuclear atypia, widespread crypt elongation, increased crypt fission and reduction in villous length
|
• in tamoxifen-treated mice
|
• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice
|
• reduced numbers in tamoxifen-treated mice
|
• elongated in tamoxifen-treated mice
|
• altered distribution in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma
• 5 of 6 tumors are located in the caecum
|
• tamoxifen-treated mice exhibit increased incidence of tumorigenesis, including lymphomas/leukemias and solid tumors (angiosarcoma, gastrointestinal adenoma, gastrointestinal adenocarcinoma and lung carcinoma)
|
• in 6 of 16 tamoxifen-treated mice, 2 of which are adenomas with high-grade dysplasia and 2 are invasive adenocarcinoma
• 5 of 6 tumors are located in the caecum
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• tamoxifen-treated mice exhibit zone 3 hydropic changes indicative of malnutrition unlike control mice
|
• in tamoxifen-treated mice
|
• tamoxifen-treated mice exhibit a decrease of Alcian Blue positive goblet cells compared with control mice
|
• tamoxifen-treated mice exhibit increased cell proliferation in the intestinal epithelium compared with control mice
|
• elongated in tamoxifen-treated mice
|
• altered distribution in tamoxifen-treated mice
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• authors state that tamoxifen-treated mice exhibit similar phenotype as Nrbp1tm1.1Dja/Nrbp1tm1.1Dja Gt(ROSA)26Sortm1(cre/ERT)Brn/ Gt(ROSA)26Sor+ mice
|
• abnormal goblet cell production in tamoxifen-treated mice
|
• abnormal granularization of Paneth cells in tamoxifen-treated mice
|
• abnormal localization of Paneth cells in tamoxifen-treated mice
|
• abnormal granularization of Paneth cells in tamoxifen-treated mice
|
• abnormal localization of Paneth cells in tamoxifen-treated mice
|
• abnormal goblet cell production in tamoxifen-treated mice
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 12/10/2024 MGI 6.24 |
![]() |
|